Symptom Impact of First-Line Dacomitinib versus Gefitinib in EGFR-Positive NSCLC: Results from a Randomized Phase 3 Study

Por: Migliorino, MR, Mok, T, Wu, Y, Zhou, X, Lee, KH, Nakagawa, K, Niho, S, Tsuji, F, Linke, R, Rosell, R, Corral, J, Pluzanski, A, Sbar, E, Sandin, R, Reisman, A, Wang, T, White, JL and Cheng, Y

---

Publicada: 1 nov 2017

---

---

Filiaciones:
Migliorino, MR:
 San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

Mok, T:
 Chinese Univ Hong Kong, Hong Kong, Peoples R China

Wu, Y:
 Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China

 Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

Zhou, X:
 Third Mil Univ, Affiliated Hosp 1, Chongqing, Peoples R China

Lee, KH:
 Chungbuk Natl Univ Hosp, Chungcheongbuk Do, South Korea

Nakagawa, K:
 Kindai Univ Hosp, Osaka, Japan

Niho, S:
 Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

Tsuji, F:
 Sfj Pharma Japan KK, Osaka, Japan

Linke, R:
 Sfj Pharmaceut Grp, Pleasanton, CA USA

:
 Germans Trias & Pujol Hlth Sci Inst, Catalan Inst Oncol, Barcelona, Spain

Corral, J:
 Hosp Univ Virgen Rocio, Seville, Spain

Pluzanski, A:
 Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland

Sbar, E:
 Pfizer Oncol, Collegeville, PA USA

Sandin, R:
 Pfizer Oncol, Stockholm, Sweden

Reisman, A:
 Pfizer Oncol, New York, NY USA

Wang, T:
 Pfizer Oncol, Groton, CT USA

White, JL:
 Pfizer Oncol, Groton, CT USA

Cheng, Y:
 Jilin Prov Canc Hosp, Changchun, Jilin, Peoples R China